Co-Morbid Insomnia and Sleep Apnea (COMISA) PDF

brain sciences Review Co-Morbid Insomnia and Sleep Apnea (COMISA): Prevalence, Consequences, Methodological Considerations, and Recent Randomized Controlled Trials Alexander Sweetman 1, * , Leon Lack 2 and Célyne Bastien 3 1 The Adelaide Institute for Sleep Health: A Flinders Centre o...

brain sciences Review Co-Morbid Insomnia and Sleep Apnea (COMISA): Prevalence, Consequences, Methodological Considerations, and Recent Randomized Controlled Trials Alexander Sweetman 1, * , Leon Lack 2 and Célyne Bastien 3 1 The Adelaide Institute for Sleep Health: A Flinders Centre of Research Excellence, Box 6 Mark Oliphant Building, 5 Laffer Drive, Bedford Park, Flinders University, Adelaide 5042, South Australia, Australia 2 The Adelaide Institute for Sleep Health: A Flinders Centre of Research Excellence, College of Education Psychology and Social Work, Flinders University, Adelaide 5042, South Australia, Australia; [email protected] 3 School of Psychology, Félix-Antoine-Savard Pavilion, 2325, rue des Bibliothèques, local 1012, Laval University, Quebec City, QC G1V 0A6, Canada; [email protected] * Correspondence: [email protected]; Tel.: +61-8-7421-9908


Received: 15 November 2019; Accepted: 10 December 2019; Published: 12 December 2019
 Abstract: Co-morbid insomnia and sleep apnea (COMISA) is a highly prevalent and debilitating disorder, which results in additive impairments to patients’ sleep, daytime functioning, and quality of life, and complex diagnostic and treatment decisions for clinicians. Although the presence of COMISA was first recognized by Christian Guilleminault and colleagues in 1973, it received very little research attention for almost three decades, until the publication of two articles in 1999 and 2001 which collectively reported a 30%–50% co-morbid prevalence rate, and re-ignited research interest in the field. Since 1999, there has been an exponential increase in research documenting the high prevalence, common characteristics, treatment complexities, and bi-directional relationships of COMISA. Recent trials indicate that co-morbid insomnia symptoms may be treated with cognitive and behavioral therapy for insomnia, to increase acceptance and use of continuous positive airway pressure therapy. Hence, the treatment of COMISA appears to require nuanced diagnostic considerations, and multi-faceted treatment approaches provided by multi-disciplinary teams of psychologists and physicians. In this narrative review, we present a brief overview of the history of COMISA research, describe the importance of measuring and managing insomnia symptoms in the presence of sleep apnea, discuss important methodological and diagnostic considerations for COMISA, and review several recent randomized controlled trials investigating the combination of CBTi and CPAP therapy. We aim to provide clinicians with pragmatic suggestions and tools to identify, and manage this prevalent COMISA disorder in clinical settings, and discuss future avenues of research to progress the field. Keywords: COMISA; insomnia; obstructive sleep apnea; sleep-disordered breathing; cognitive behavior therapy for insomnia; continuous positive airway pressure 1. Introduction 1.1. Insomnia and Obstructive Sleep Apnea Insomnia and obstructive sleep apnea (OSA) are the two most common sleep disorders, which both include nocturnal sleep disturbances, impairments to daytime functioning, mood, and quality of life, Brain Sci. 2019, 9, 371; doi:10.3390/brainsci9120371 www.mdpi.com/journal/brainsci Brain Sci. 2019, 9, 371 2 of 18 and high healthcare utilization. As this review focuses on patients with co-morbid insomnia and sleep apnea (COMISA), a brief introduction to both insomnia and OSA is provided below. Insomnia disorder is characterized by frequent and chronic self-reported difficulties initiating sleep, maintaining sleep, and early morning awakenings from sleep, which are associated with impaired daytime functioning, mood, and quality of life [1,2]. Insomnia disorder is thought to result from a combination of pre-disposing, precipitating, and perpetuating factors, and is conceptualized as a self-perpetuating disorder including elevated cognitive and physiological ‘hyper-arousal’ [3–5]. The estimated prevalence of insomnia varies widely according to diagnostic criteria and specific populations of interest, however it is thought that 6%–10% of the general population suffer from chronic insomnia disorder, which includes clinically significant and frequent nocturnal sleep disturbances and impaired daytime functioning [6,7]. Although cognitive and behavioral therapy for insomnia (CBTi) leads to long-term improvement of insomnia and is the recommended ‘first line’ insomnia treatment [8–11], a lack of access to CBTi has resulted in the majority of insomnia sufferers receiving prescriptions for sedative-hypnotic medications as the initial and ongoing treatment [12,13]. Alternatively, OSA is characterized by repetitive brief closure (apnea) or narrowing (hypopnea) of the pharyngeal airway during sleep which result in the cessation or reduction of airflow, reduced oxygen saturation, and commonly terminate in post-apneic arousals from sleep, increased sympathetic activity, and the resumption of airflow [1,14,15]. OSA is thought to result from a combination of anatomical (e.g., a narrow pharyngeal airway), and non-anatomical factors (e.g., impaired upper airway muscle function, low arousal threshold, and unstable control of breathing). The combination of frequent respiratory events and arousals from sleep throughout the night severely fragments sleep architecture, resulting in perceptions of chronically non-restorative sleep, reduced quality of life, excessive daytime sleepiness, and increased risk of motor-vehicle accidents [17–19]. The most common index of OSA presence and severity is the apnea/hypopnea index (AHI), which represents the average number of respiratory events experienced per hour of sleep. Diagnostic criteria for OSA include an AHI of at least five in the presence of an associated complaint/disorder (e.g., insomnia, sleepiness, fatigue, snoring, hypertension, atrial fibrillation, congestive heart failure, etc.), or an AHI of at least 15. Mild, moderate, and severe OSA are diagnosed according to an AHI of ≥5 to